Literature DB >> 19213430

Cyclophosphamide enhances the immunosuppressive action of its own active metabolites.

L Y Telegin1, V M Pisarev, L A Pevnitsky.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 19213430     DOI： 10.1134/s0012496608060203

Source DB:  PubMed          Journal:  Dokl Biol Sci        ISSN： 0012-4966


× No keyword cloud information.
  10 in total

1.  A mouse-based strategy for cyclophosphamide pharmacogenomic discovery.

Authors:  James W Watters; Ellen F Kloss; Daniel C Link; Timothy A Graubert; Howard L McLeod
Journal:  J Appl Physiol (1985)       Date:  2003-10

2.  [Influence of several factors on the formation of immunologic memory].

Authors:  G K Baĭmukanova; N N Smirnova
Journal:  Biull Eksp Biol Med       Date:  1977-09

3.  [Immunodepressant action of cyclophosphamide in different strains of mice].

Authors:  L A Pevnitskiĭ; L Iu Telegin; V N Bol'shev
Journal:  Biull Eksp Biol Med       Date:  1977-04

4.  Immunostimulatory effects of low-dose cyclophosphamide are controlled by inducible nitric oxide synthase.

Authors:  Markus Loeffler; Jörg A Krüger; Ralph A Reisfeld
Journal:  Cancer Res       Date:  2005-06-15       Impact factor: 12.701

5.  Genetic differences in the cyclophosphamide-induced immune suppression: weaker suppression of T-cell cytotoxicity by cyclophosphamide activated by CBA mice.

Authors:  M Hurme; B E Bång; M Sihvola
Journal:  Clin Immunol Immunopathol       Date:  1980-09

Review 6.  Mammalian cytochromes P450--importance of tissue specificity.

Authors:  Matej Seliskar; Damjana Rozman
Journal:  Biochim Biophys Acta       Date:  2006-10-03

7.  Adoptive transfer of T(reg) depleted autologous T cells in advanced renal cell carcinoma.

Authors:  Fiona C Thistlethwaite; Eyad Elkord; Richard W Griffiths; Deborah J Burt; Alaaeldin M Shablak; John D M Campbell; David E Gilham; Eric B Austin; Peter L Stern; Robert E Hawkins
Journal:  Cancer Immunol Immunother       Date:  2007-09-27       Impact factor: 6.968

Review 8.  Carboxypeptidase-G2-based gene-directed enzyme-prodrug therapy: a new weapon in the GDEPT armoury.

Authors:  Douglas Hedley; Lesley Ogilvie; Caroline Springer
Journal:  Nat Rev Cancer       Date:  2007-11       Impact factor: 60.716

9.  Cross-linking of DNA in L1210 cells and nuclei treated with cyclophosphamide and phosphoramide mustard.

Authors:  Y A Surya; J M Rosenfeld; B L Hillcoat
Journal:  Cancer Treat Rep       Date:  1978-01

10.  Sensitivity to immunodepressant action of cyclophosphamide: analysis of interstrain differences in mice.

Authors:  L A Pevnitsky; G F Zhirnov; A V Mazurov; V V Viktorov
Journal:  Int J Immunopharmacol       Date:  1985
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.